SciELO - Scientific Electronic Library Online

vol.45 número1Experiencia en Nefrectomía Parcial y Enucleación de Tumor Renal Laparoscópico “Zero Isquemia”, en Cochabamba, BoliviaInjerto Autólogo de Calcar Femoral como Contrafuerte para Artroplastía en Fracturas Laterales de Cadera índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • No hay articulos similaresSimilares en SciELO


Gaceta Médica Boliviana

versión impresa ISSN 1012-2966versión On-line ISSN 2227-3662


LIMACHI CHOQUE, Jhonny Wilson  y  VERDUGUEZ-ORELLANA, Aleida. Post-vaccination Anti SARS-CoV-2 Antibodies in Cochabamba, Bolivia. Gac Med Bol [online]. 2022, vol.45, n.1, pp.29-35. ISSN 1012-2966.

Neutralizing antibodies (NAbs) against SARS-CoV-2 are being evaluated in humans. The specific adaptive responses of asymptomatic or symptomatic subjects against SARS-CoV-2 antigen show a positive correlation with the humoral immune response.


To evaluate the presence of antibodies against spike specific protein (RBD, receptor binding domain of spike protein) and NP (nucleoprotein) of SARS-CoV-2 virus in people who received anti-COVID-19 vaccines used in Bolivia.


During 2021 between July and August, a cross-sectional observational study was carried out in 150 persons of both sexes who were recruited in the Hospitals: Caja de Seguro Social Militar and Caja Nacional de Salud, to detect specific antibodies against the NP and RBD proteins of the SARS-CoV-2 virus responsible for COVID-19, by means of a qualitative immunochromatographic test.


The presence of neutralizing antibodies after the administration of vaccines against SARS-CoV-2, as complete scheme, first dose, and/or history of infection, was found in 61 % of the persons grouped in the category "low occupational risk" in a heterogeneous way regarding RBD antibodies, NP or both together.


The production of antibodies against the specific protein of the RBD and NP spike of the SARS-CoV-2 virus shows a heterogeneous response due to several factors such as, type of vaccine, number of doses, infection by COVID-19, antibody decline over time, sensitivity of the test and intrinsic properties of the person evaluated.

Palabras clave : SARS-CoV-2; antibodies; vaccines.

        · resumen en Español     · texto en Español     · Español ( pdf )